

HOPE BTK Registry

Treatment of BTK lesions in high-risk patients suffering from Chronic Limb Threatening Ischemia



COMPLEX CLTI COHORT

Diabetes

91% vs 89%

ASA Score (3)

78% vs 76%

WIFI Score

4.1 ± 1.8 vs 3.9 ± 1.9

ESRD


23% vs 22%

PRINCIPAL INVESTIGATOR : PROF. EDWARD CHOKE

3 Year Clinical Outcomes*

Freedom from TLR


MT PTA **76.5%**
POBA **64.9%**



Number at Risk	0	6	12	18	24	30	36
POBA	185	109	86	74	64	59	49
Sirolimus DCB	133	92	88	79	72	67	57

Freedom from Major Amputation


MT PTA **92.8%**
POBA **85.7%**



Number at Risk	0	6	12	18	24	30	36
POBA	185	135	120	108	98	91	77
Sirolimus DCB	133	109	107	100	91	85	74

Amputation Free Survival


MT PTA **60.9%**
POBA **47.4%**



Number at Risk	0	6	12	18	24	30	36
POBA	185	140	126	116	105	97	81
Sirolimus DCB	133	109	108	104	93	87	76

Overall Survival

MT PTA **62.4%**
POBA **53.9%**



Number at Risk	0	6	12	18	24	30	36
POBA	185	152	138	128	117	109	92
Sirolimus DCB	133	111	110	106	95	89	78

Key Takeaways

MagicTouch PTA, compared to POBA, was associated with lower BTK re-intervention, better AFS and survival rate. Long term sustained efficacy and safety upto 3 years indicate the superiority of MagicTouch PTA versus POBA in BTK.

*Presented by Prof. Edward Choke at Charing Cross 2025

